Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medication Adherence to Single vs Multiple Topical Acne Medications
NCT05582434Phase 1Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clindamycin phosphate + adapalene + benzoyl peroxide in acne vulgaris (3 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Medication Adherence at 56 days. Started Feb 2024; status: active, not recruiting.
02
Drugs
clindamycin phosphate + adapalene + benzoyl peroxide
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05582434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582434.